The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on experimental therapies and challenging drug development programs, has fueled what some are calling "High Roller https://prestontaro438133.verybigblog.com/39041342/high-stakeholder-pharma-speculative-investment